Max Jan
Impact in
- Hematology top 1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Immunology top 2%
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- Immune cells in cancer
- Immunotherapy and Immune Responses
Papers in
-
- Protein Degradation and Inhibitors 8
- CRISPR and Genetic Engineering 5
- Oncology 13
- CAR-T cell therapy research 13
- Co-authors
- Ravindra Majeti (8 shared papers)Irving L. Weissman (8 shared papers)Mark P. Chao (4 shared papers)Ash A. Alizadeh (5 shared papers)Benjamin L. Ebert (10 shared papers)Thomas M. Snyder (3 shared papers)Stephen R. Quake (3 shared papers)Paresh Vyas (1 shared paper)
- Journals
- Blood (7 papers)Cancer Research (4 papers)Science Translational Medicine (2 papers)Blood Advances (2 papers)ACS Chemical Biology (1 paper)
- Partner nations
- United StatesIndiaSpain
In The Last Decade
Max Jan
28 papers receiving 3.0k citations
Max Jan's Hit Papers
Peers
Comparison fields: 5 of 86
- Hematology 727
- Immunology 1.3k
- Oncology 1.1k
- Aging 57
- Genetics 243
Countries citing papers authored by Max Jan
This map shows the geographic impact of Max Jan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Jan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Jan more than expected).
Fields of papers citing papers by Max Jan
This network shows the impact of papers produced by Max Jan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Jan. The network helps show where Max Jan may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Jan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma Hit paper breakdown → | 2010 | 874 |
| 2 | Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia Hit paper breakdown → | 2012 | 548 |
| 3 | 2010 | 307 | |
| 4 | 2011 | 254 | |
| 5 | CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours Hit paper breakdown → | 2022 | 233 |
| 6 | 2021 | 195 | |
| 7 | 2021 | 99 | |
| 8 | 2011 | 97 | |
| 9 | 2022 | 91 | |
| 10 | 2016 | 81 | |
| 11 | 2023 | 80 | |
| 12 | 2021 | 71 | |
| 13 | 2024 | 21 | |
| 14 | 2011 | 18 | |
| 15 | 2020 | 9 | |
| 16 | 2023 | 8 | |
| 17 | 2022 | 6 | |
| 18 | 2023 | 5 | |
| 19 | 2015 | 5 | |
| 20 | 2021 | 4 |
About Max Jan
Max Jan is a scholar working on Molecular Biology, Oncology, Hematology, Immunology and Cancer Research, having authored 29 papers that have together received 3.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (13 papers), Protein Degradation and Inhibitors (8 papers), Acute Myeloid Leukemia Research (8 papers), CRISPR and Genetic Engineering (5 papers), Phagocytosis and Immune Regulation (4 papers), Cancer Genomics and Diagnostics (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Nanowire Synthesis and Applications (3 papers). The work is most often cited by research in Hematology (727 citations), Immunology (1.3k citations), Oncology (1.1k citations), Aging (57 citations) and Genetics (243 citations). Max Jan has collaborated with scholars based in United States, India and Spain. Frequent co-authors include Ravindra Majeti, Irving L. Weissman, Mark P. Chao, Ash A. Alizadeh, Benjamin L. Ebert, Thomas M. Snyder, Stephen R. Quake, Paresh Vyas, M. Ryan Corces and Chad Tang. Their work appears in journals such as Blood, Cancer Research, Science Translational Medicine, Blood Advances and ACS Chemical Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.